Clinical Trial

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

CINCINNATI, Ohio, June 28, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a…

1 year ago

ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity

Lupus Nephritis (“LN”) is characterized by inflammation in the kidney, protein leakage into the urine (“proteinuria”), and progressive kidney damageNLRP3…

1 year ago

Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome

NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…

1 year ago

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug developmentDr. Chong…

1 year ago

First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

Topline data expected in July 2023BOCA RATON, Fla., June 28, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First…

1 year ago

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma

- Clinical data support safety and tolerability profile of FHD-286, a highly potent, - selective, allosteric, oral, small molecule inhibitor…

1 year ago

Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

Results Show Positive Treatment Effect of CT1812 on Global and Regional Brain Activity Management Holding Webcast Conference Call at 8:00am…

1 year ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update

RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis…

1 year ago

Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla

SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of…

1 year ago

Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein

Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein Siena, Italy,…

1 year ago